Picture [iito] Made Without Love 650x80px
Document › Details

Protea Biosciences Group, Inc.. (6/16/14). "Press Release: Protea Announces Ion Mobility Mass Spec Imaging Services. Ion Mobility for Metabolite and Lipid Profiling Is Added to its Mass Spectrometry-based Molecular Imaging Services Portfolio". Morgantown

Region Region Baltimore, MD
  Country United States (USA)
Organisations Organisation Protea Biosciences Group Inc.
  Group Protea Biosciences (Group)
  Organisation 2 Waters Corporation (NYSE: WAT)
  Group Waters (Group)
Products Product mass spectrometry services (MS services)
  Product 2 Synapt® G2-S HDMS system
Index term Index term Protea Biosciences–Waters: mass spectrometer, 2012c supply acquisition of Waters Synapt G2-S HDMS by Protea’s Bioanalytical Lab
Person Person Kilby, Greg (Protea 201404– Chief Bioanalytics Officer before Thermo Fisher + Agilent + Pfizer)

Protea Biosciences Group, Inc. (OTCQB:PRGB) ("Protea"), announced that it will be expanding its existing mass spectrometry based molecular imaging by offering Ion Mobility on a Waters Synapt® G2S High Definition mass spectrometer as a powerful extension to Protea's portfolio of mass spectrometry based molecular imaging services.

"Ion mobility allows the separation of ions in the mass spectrometer based on their size and shape as well as their mass to charge ratio. In combination with the LAESI-MS process, ion mobility provides an orthogonal dimension of separation to help differentiate classes of molecules such as lipids, metabolites, peptides and proteins", said Dr. Greg Kilby, Protea's Director of Molecular Imaging and Bioanalytical Services. He added, "This process results in improved sensitivity, specificity, and confidence in identification of putative biomarkers. Ion mobility is a very powerful tool we can use to extend our in-situ metabolite and lipid profiling capabilities. Protea is uniquely positioned in the industry to provide our client's access to combinations of both ion mobility and LAESI-MS based molecular imaging."

Protea has developed several new applications utilizing ion mobility combined with LAESI-MS imaging in areas as diverse as biomarkers of wound healing and in-situ lipid profiling of Alzheimer brain tissue. These, along with other new applications, will be presented at the American Society of Mass Spectrometry Annual Conference in Baltimore, MD. The Conference will take place at the Baltimore Convention Center,
located at 1 West Pratt Street, Baltimore, MD 21201 from Sunday June 15th through Thursday June 19th.

Details about Protea's ASMS presence can be found through the following link:

About Protea Biosciences Group, Inc.

Protea Biosciences (OTCQB:PRGB) is a commercial stage molecular information company, focused on meeting the needs of the pharmaceutical, biotechnology, agriculture, chemical and other industries with innovative bioanalytical technologies, Protea's proprietary technology, LAESI® (Laser Ablation Electrospray Ionization), is used with mass spectrometry to identify large numbers of distinct molecules from single analyses of tissues, cells, fluids, agricultural specimens and other sample types. Using proprietary software (ProteaPlotTM), the location of each distinct molecule in a respective sample can be displayed, enabling direct molecular imaging. The LAESI DP-1000, an integrated system that combines LAESI and ProteaPlot, is marketed to a wide array of researchers for numerous applications. Protea maintains its own laboratory facility where it performs services using LAESI and complementary technologies for a wide array of customers to support preclinical pharmaceutical R&D, biomarker discovery and other applications.

Forward-Looking Statements

This press release may contain certain statements relating to future results which are forwardlooking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further information concerning the Company and its business, including factors that potentially could materially affect the Company's financial results, are contained in the Company's filings with the Securities and Exchange Commission. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

For more Information:
Protea Biosciences Group, Inc., 955 Hartman Run Road, Morgantown, WV 26505 USA
Phone: 304.292.2226 Fax: 304.292.7101

Protea and LAESI are registered trademarks of Protea Biosciences Group, Inc.

Record changed: 2016-03-19


Picture Fairtec GmbH Worldwide Event Solutions 650x65px

More documents for Protea Biosciences (Group)

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to and simply fill the subject line with the word »MSC Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at and


Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px

» top